Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Over $75,000 in Humacyte to Contact Him Directly to Discuss Their Options.
If you have a loss of more than $75,000 per Humacyte between May 10, 2024 and October 17, 2024 and you would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson live to 877-247-4292 or 212-983-9330 (Ext. 1310).
(You can also click here for more information)
New York, New York–(Newsfile Corp. – December 28, 2024) – Faruqi & Faruqi, LLP, a leading national defense law firm, is investigating potential claims against Humacyte, Inc. (“Humacyte” or the “Company”). (NASDAQ: HUMA) and remind investors of January 17, 2025 deadline seeking the role of lead plaintiff in a federal class action against the Company.
Faruqi & Faruqi is a leading national security law firm with offices in New York, Pennsylvania, California and Georgia. The firm has raised hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As described below, the complaint alleges that the Company and its directors violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) that the agency The company in Durham, North Carolina failed to adapt to the good proposal. procedures, including quality assurance and biological testing; (2) that FDA review of the BLA will be delayed while Humacyte corrects these deficiencies; and (3) that, as a result, there was a significant risk of FDA approval of ATEV for nerve damage; and (4) that, as a result of the foregoing, Defendants’ positive statements regarding the Company’s business, operations, and prospects were misleading and/or had no reasonable basis.
On August 9, 2024, after the market closed, Humacyte issued a press release announcing that the Food and Drug Administration (“FDA”) “will require additional time to complete its review of the License Application of the Biologic License (BLA) for acellular tissues made. vessel (ATEV) in the indication of vascular infection.” The press release disclosed in part that, “(d) while continuing the review of the BLA, the FDA has conducted an inspection of our manufacturing processes and clinical sites and has engaged in numerous discussions with us about uploading our BLA file(.)”
In this news, the price of the Company’s stock fell by $1.29, or 16.4%, to close at $6.62 per share on August 12, 2024, in unusually heavy volume.
On October 17, 2024, during market hours, the FDA released a Form 483 regarding Humacyte’s facility in Durham, North Carolina, which disclosed numerous violations, including “no verification of biological quality, ” “no biological testing,” and “inadequate quality care.” .”
On this news, the Company’s stock price decreased by $0.95, or 16.35%, to close at $4.86 per share on October 17, 2024, in unusually heavy volume.
The lead plaintiff appointed by the court is the investor with the greatest financial interest in the relief sought by a reasonable and common class of class members conducting and overseeing the case on behalf of the putative class. Any member of the arbitration panel may have the Court act as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent panel member. Your ability to participate in any recovery is not affected by the decision to serve as the lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information about Humacyte’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Follow us for updates on LinkedIn, on X, or on Facebook (NASDAQ:).
Advertising Attorney. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Preliminary results do not guarantee or predict the same result with respect to any future issue. We welcome the opportunity to discuss your matter. All communications will be held confidentially.
To view the source version of this release, please visit https://www.newsfilecorp.com/release/234707
